Table 2.
Cytotoxicity (IC50) of DMC against different cancer cell lines.
| Cancer cell line | Description | IC50 (μm) | Reference |
|---|---|---|---|
| P-388 | Mouse lymphoid neoplasm | 10.31 | [25] |
| KB | Human epidermoid carcinoma in the mouth | 15.90 | — |
| MCF-7 | Human breast cancer | 14.51 | — |
| A549 | Human lung cancer | 13.04 | — |
| ASK | Rat glioma | 9.00 | — |
| PANC-1 | Human pancreas | 10.5 ± 0.8 | [39] |
| MIA-PACA2 | Human pancreatic carcinoma | 12.2 ± 0.9 | — |
| SMMC-7721 | Liver cancer | 32.3 ± 1.13 | [23] |
| 8898 | Pancreas cancer | 37.2 ± 2.15 | — |
| SPC-A-1 | Lung cancer | 84.6 ± 4.36 | — |
| HeLa | Tumor of cervix uteri | 37.7 ± 1.64 | — |
| 95-D | High metastatic lung carcinoma | 84.8 ± 4.71 | — |
| GBC-SD | Gall bladder carcinoma | 81.3 ± 2.75 | — |
| A549 | Human lung cancer | 2.3 ± 0.44 | [38] |
| HepG2 | Human liver cancer | 8.3 ± 0.22 | — |
| MCF-7 | Human breast cancer | 15.1 ± 0.72 | — |
| HeLa | Tumor of cervix uteri | 11.8 ± 0.42 | — |
| HeLa/Tax | Taxol-resistant HeLa cells | 15.3 ± 0.19 | — |